AU2017371416B2 - Nucleic acid-based assembly and use thereof in cancer therapy - Google Patents

Nucleic acid-based assembly and use thereof in cancer therapy Download PDF

Info

Publication number
AU2017371416B2
AU2017371416B2 AU2017371416A AU2017371416A AU2017371416B2 AU 2017371416 B2 AU2017371416 B2 AU 2017371416B2 AU 2017371416 A AU2017371416 A AU 2017371416A AU 2017371416 A AU2017371416 A AU 2017371416A AU 2017371416 B2 AU2017371416 B2 AU 2017371416B2
Authority
AU
Australia
Prior art keywords
nucleic acid
cancer
cell
carcinoma
aptamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017371416A
Other languages
English (en)
Other versions
AU2017371416A1 (en
Inventor
Volker Adam
Michael Famulok
Stephan Irsen
Deepak PRUSTY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rheinische Friedrich Wilhelms Universitaet Bonn
Stiftung Caesar Center of Advanced European Studies and Research
Original Assignee
Univ Bonn Rheinische Friedrich Wilhelms
Rheinische Friedrich Wilhelms Universitaet Bonn
Stiftung Caesar Center of Advanced European Studies and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bonn Rheinische Friedrich Wilhelms, Rheinische Friedrich Wilhelms Universitaet Bonn, Stiftung Caesar Center of Advanced European Studies and Research filed Critical Univ Bonn Rheinische Friedrich Wilhelms
Publication of AU2017371416A1 publication Critical patent/AU2017371416A1/en
Application granted granted Critical
Publication of AU2017371416B2 publication Critical patent/AU2017371416B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909—Micelles formed by phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017371416A 2016-12-07 2017-12-07 Nucleic acid-based assembly and use thereof in cancer therapy Active AU2017371416B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16202754.4 2016-12-07
EP16202754.4A EP3332812A1 (fr) 2016-12-07 2016-12-07 Ensemble à base d'acide nucléique et utilisation de l'ensemble dans la thérapie du cancer
PCT/EP2017/081933 WO2018104492A1 (fr) 2016-12-07 2017-12-07 Assemblage à base d'acide nucléique, et utilisation de ce dernier dans le traitement du cancer

Publications (2)

Publication Number Publication Date
AU2017371416A1 AU2017371416A1 (en) 2019-06-27
AU2017371416B2 true AU2017371416B2 (en) 2023-11-09

Family

ID=57681234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017371416A Active AU2017371416B2 (en) 2016-12-07 2017-12-07 Nucleic acid-based assembly and use thereof in cancer therapy

Country Status (6)

Country Link
US (1) US20200123547A1 (fr)
EP (2) EP3332812A1 (fr)
AU (1) AU2017371416B2 (fr)
CA (1) CA3046280A1 (fr)
IL (2) IL308070A (fr)
WO (1) WO2018104492A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022120338A1 (fr) * 2020-12-03 2022-06-09 University Of Florida Research Foundation, Inc. Assemblages d'aptamères pour la réticulation de protéines
CN113248556B (zh) * 2021-05-18 2022-07-26 武汉科技大学 一种核酸枝接偶氮苯的组装体及制备方法及应用
CN113567685B (zh) * 2021-09-26 2022-05-17 瑞博奥(广州)生物科技股份有限公司 基于核酸适配体探针的hgfr识别方法及检测hgfr的试剂盒
CN113980959B (zh) * 2021-10-27 2023-10-24 闽江学院 一种“y型”多功能dna纳米组装体、制备方法及其应用
CN116240213A (zh) * 2022-08-10 2023-06-09 中山大学 光响应型核酸适配体、光启动dna聚合酶及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071852A2 (fr) * 2008-12-19 2010-06-24 University Of Florida Research Foundation, Inc. Micelles oligonucléotidiques

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5853984A (en) 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5789163A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US5789157A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5712375A (en) 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
ES2110444T3 (es) 1990-06-11 1998-02-16 Nexstar Pharmaceuticals Inc Ligandos de acidos nucleicos.
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5763566A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5864026A (en) 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
WO1996034875A1 (fr) 1995-05-03 1996-11-07 Nexstar Pharmaceuticals, Inc. Evolution systematique des ligands par enrichissement exponentiel: procede selex pour tissus
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
PT957929E (pt) 1996-10-25 2006-06-30 Gilead Sciences Inc Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
EP1481090A4 (fr) 2002-02-15 2006-08-09 Somalogic Inc Methodes et reactifs destines a la detection d'une liaison de cibles par des ligands d'acides nucleiques
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
KR101337684B1 (ko) * 2011-10-17 2013-12-30 성균관대학교산학협력단 표적지향 및 치료가 가능한 다기능성 핵산 기반 항암제, 이의 제조 방법 및 이를 포함하는 항암제 조성물
JP6123794B2 (ja) * 2012-03-28 2017-05-10 日本電気株式会社 標的物質の検出方法、検査キット、および検出装置
AU2015213483B2 (en) * 2014-02-05 2020-07-02 Deakin University Aptamer construct
WO2016050850A1 (fr) * 2014-10-02 2016-04-07 Guenter Mayer Procédé d'identification ou de production d'un aptamère
US10821189B2 (en) * 2015-04-10 2020-11-03 The Methodist Hospital System CD38 ligand-drug conjugates for targeted cancer therapy
US11572557B2 (en) * 2018-01-29 2023-02-07 The Board Of Trustees Of The Leland Stanford Junior University Photoreversible acylation reagents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071852A2 (fr) * 2008-12-19 2010-06-24 University Of Florida Research Foundation, Inc. Micelles oligonucléotidiques

Also Published As

Publication number Publication date
IL267155B1 (en) 2023-12-01
US20200123547A1 (en) 2020-04-23
IL267155B2 (en) 2024-04-01
IL308070A (en) 2023-12-01
AU2017371416A1 (en) 2019-06-27
EP3551229A1 (fr) 2019-10-16
WO2018104492A1 (fr) 2018-06-14
CA3046280A1 (fr) 2018-06-14
EP3332812A1 (fr) 2018-06-13
IL267155A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
AU2017371416B2 (en) Nucleic acid-based assembly and use thereof in cancer therapy
Zhu et al. Aptamer-based targeted therapy
Zhou et al. Aptamers: A promising chemical antibody for cancer therapy
AU2013206989B2 (en) High-efficiency nanoparticle-type double-helical oligo-RNA structure and method for preparing same
EP3047026B1 (fr) Nanoparticules d'arn multifonctionnelles et procédés d'utilisation
CN105705638B (zh) 改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法
JP2019513692A (ja) 核酸キャリア及び治療上の使用方法
WO2007075680A2 (fr) Systeme et procede d'administration d'un materiau a une cellule
JP2023531122A (ja) 材料足場を使用した哺乳類細胞の増強されたウイルス形質導入
Fu et al. Emerging Progress of RNA-Based Antitumor Therapeutics
KR20230164124A (ko) 구형 핵산 백신 구조를 사용한 다중 t 세포 유형 표적화
WO2021221783A1 (fr) Procédés d'identification de ligands de ciblage de récepteur antigénique chimérique et leurs utilisations
KR20220131621A (ko) 압타머기반 입자 및 이의 제조방법
WO2021221782A1 (fr) Ligands chimériques ciblant des récepteurs antigéniques et leurs utilisations
KR20210116861A (ko) 압타머기반 입자 및 이의 제조방법
Tan et al. Aptamer properties, functions, and applications
US20230416758A1 (en) Trna fragments and methods of use
Akhtar Pharmacological reprogramming of macrophages through aptamiRs
Chen Advancing Oligonucleotide Therapeutics: Novel Delivery Strategies Explored Through Polymer Conjugates
CN117157104A (zh) 使用球形核酸疫苗架构靶向多种t细胞类型
WO2022104006A9 (fr) Aptamères de gpc3, variants et utilisation associée
CN118265791A (en) Spherical nucleic acids for cGAS-STING and STAT3 pathway modulation for immunotherapeutic treatment of cancer
Abdelaal ENHANCING MIRNA THERAPEUTICS USING LIGAND CONJUGATED AND CHEMICALLY MODIFIED TUMOR SUPPRESSIVE MIRNAS
KR20210116860A (ko) 압타머기반 입자 및 이의 제조방법
CN114222616A (zh) Rna和包含该rna的核酸载体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)